Treatment of Neurodegenerative Pathologies Using Undifferentiated Mesenchymal Stem Cells

  • Arianna ScuteriEmail author
Part of the Stem Cells and Cancer Stem Cells book series (STEM, volume 6)


Neurodegenerative diseases are very disabling disorders affecting central and peripheral nervous systems, characterized by neuronal loss, inflammatory reaction, and direct or indirect involvement of the immune system. Currently there are no effective treatments to counteract the progressive neuronal degeneration and, for this reason, neurodegenerative diseases are good targets for cell therapy approaches based on the use of Mesenchymal Stem Cells. Initially attracting interest because of their supposed differentiation potential towards neural lineages, it is now largely recognized that undifferentiated Mesenchymal Stem Cells can exert a trophic and protective action on neurons and glial cells. The neuroprotective effect is mediated by the immunomodulatory properties of Mesenchymal Stem Cells and by their ability to release soluble trophic factors that counteract neuronal death and stimulate the endogenous neurogenesis. The promising results obtained up to now in pre-clinical studies on different neurodegenerative disease models and the preliminary data from clinical trials lead one to conclude that MSCs may represent an important therapeutic prospect.


Amyotrophic Lateral Sclerosis Brain Derive Neurotrophic Factor Neuronal Survival Amyotrophic Lateral Sclerosis Patient Glial Derive Neurotrophic Factor 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.



I am grateful to Prof. G. Tredici for his useful suggestions, to Dr. E Donzelli for the design of Fig. 16.1 and to E. Genton for the English revision of the text.

This work has been supported by Ministero Italiano Università e Ricerca (MIUR) – Firb Futuro in Ricerca 2008 Prot. N° RBFR08VSVI_001.


  1. Blandini F, Cova L, Armentero MT, Zennaro E, Levandis G, Bossolasco P, Calzarossa C, Mellone M, Busca G, Lambertenghi Deliliers G, Polli E, Nappi G, Silani V (2010) Transplantation of undifferentiated human mesenchymal stem cells protects against 6-hydroxydopamine neurotoxicity in the rat. Cell Transplant 19:203–217PubMedCrossRefGoogle Scholar
  2. Bossolasco P, Cova L, Calzarossa C, Servida F, Mencacci NE, Onida F, Polli E, Lambertenghi Deliliers G, Silani V (2010) Metalloproteinase alterations in the bone marrow of ALS patients. J Mol Med (Berl) 88:553–564CrossRefGoogle Scholar
  3. Camp DM, Loeffler DA, Farrah DM, Borneman JN, LeWitt PA (2009) Cellular immune response to intrastriatally implanted allogeneic bone marrow stromal cells in a rat model of Parkinson’s disease. J Neuroinflammation 6:17PubMedCrossRefGoogle Scholar
  4. Chamberlain G, Fox J, Ashton B, Middleton J (2007) Concise review: mesenchymal stem cells: their phenotype, differentiation capacity, immunological features, and potential for homing. Stem Cells 25:2739–2749PubMedCrossRefGoogle Scholar
  5. Choi MR, Kim HY, Park JY, Lee TY, Baik CS, Chai YG, Jung KH, Park KS, Roh W, Kim KS, Kim SH (2010) Selection of optimal passage of bone marrow-derived mesenchymal stem cells for stem cell therapy in patients with amyotrophic lateral sclerosis. Neurosci Lett 472:94–98PubMedCrossRefGoogle Scholar
  6. Constantin G, Marconi S, Rossi B, Angiari S, Calderan L, Anghileri E, Gini B, Bach SD, Martinello M, Bifari F, Galiè M, Turano E, Budui S, Sbarbati A, Krampera M, Bonetti B (2009) Adipose-derived mesenchymal stem cells ameliorate chronic experimental autoimmune encephalomyelitis. Stem Cells 27:2624–2635PubMedCrossRefGoogle Scholar
  7. Cova L, Armentero MT, Zennaro E, Calzarossa C, Bossolasco P, Busca G, Lambertenghi Deliliers G, Polli E, Nappi G, Silani V, Blandini F (2010) Multiple neurogenic and neurorescue effects of human mesenchymal stem cell after transplantation in an experimental model of Parkinson’s disease. Brain Res 1311:12–27PubMedCrossRefGoogle Scholar
  8. Danielyan L, Schäfer R, von Ameln-Mayerhofer A, Bernhard F, Verleysdonk S, Buadze M, Lourhmati A, Klopfer T, Schaumann F, Schmid B, Koehle C, Proksch B, Weissert R, Reichardt HM, van den Brandt J, Buniatian GH, Schwab M, Gleiter CH, Frey WH 2nd (2011) Therapeutic efficacy of intranasally delivered mesenchymal stem cells in a rat model of Parkinson disease. Rejuvenation Res 14:3–16PubMedCrossRefGoogle Scholar
  9. Dey ND, Bombard MC, Roland BP, Davidson S, Lu M, Rossignol J, Sandstrom MI, Skeel RL, Lescaudron L, Dunbar GL (2010) Genetically engineered mesenchymal stem cells reduce behavioral deficits in the YAC 128 mouse model of Huntington’s disease. Behav Brain Res 214:193–200PubMedCrossRefGoogle Scholar
  10. Hardy SA, Maltman DJ, Przyborski SA (2008) Mesenchymal stem cells as mediators of neural differentiation. Curr Stem Cell Res Ther 3:43–52PubMedCrossRefGoogle Scholar
  11. Karussis D, Karageorgiou C, Vaknin-Dembinsky A, Gowda-Kurkalli B, Gomori JM, Kassis I, Bulte JW, Petrou P, Ben-Hur T, Abramsky O, Slavin S (2010) Safety and immunological effects of mesenchymal stem cell transplantation in patients with multiple sclerosis and amyotrophic lateral sclerosis. Arch Neurol 67:1187–1194PubMedCrossRefGoogle Scholar
  12. Kim YJ, Park HJ, Lee G, Bang OY, Ahn YH, Joe E, Kim HO, Lee PH (2009) Neuroprotective effects of human mesenchymal stem cells on dopaminergic neurons through anti-inflammatory action. Glia 57:13–23PubMedCrossRefGoogle Scholar
  13. Lee HJ, Lee JK, Lee H, Shin JW, Carter JE, Sakamoto T, Jin HK, Bae JS (2010a) The therapeutic potential of human umbilical cord blood-derived mesenchymal stem cells in Alzheimer’s disease. Neurosci Lett 481:30–35PubMedCrossRefGoogle Scholar
  14. Lee JK, Jin HK, Endo S, Schuchman EH, Carter JE, Bae JS (2010b) Intracerebral transplantation of bone marrow-derived mesenchymal stem cells reduces amyloid-beta deposition and rescues memory deficits in Alzheimer’s disease mice by modulation of immune responses. Stem Cells 28:329–343PubMedGoogle Scholar
  15. Levy YS, Stroomza M, Melamed E, Offen D (2004) Embryonic and adult stem cells as a source for cell therapy in Parkinson’s disease. J Mol Neurosci 24:353–386PubMedCrossRefGoogle Scholar
  16. Lindvall O, Rehncrona S, Gustavii B, Brundin P, Astedt B, Widner H, Lindholm T, Björklund A, Leenders KL, Rothwell JC, Frackowiak R, Marsden CD, Johnels B, Steg G, Freedman R, Hoffer BJ, Seiger L, Strömberg I, Bygdeman M, Olson L (1988) Fetal dopamine-rich mesencephalic grafts in Parkinson’s disease. Lancet 2:1483–1484PubMedCrossRefGoogle Scholar
  17. Lu Z, Hu X, Zhu C, Wang D, Zheng X, Liu Q (2009) Overexpression of CNTF in mesenchymal stem cells reduces demyelination and induces clinical recovery in experimental autoimmune encephalomyelitis mice. J Neuroimmunol 206:58–69PubMedCrossRefGoogle Scholar
  18. Mazzini L, Ferrero I, Luparello V, Rustichelli D, Gunetti M, Mareschi K, Testa L, Stecco A, Tarletti R, Miglioretti M, Fava E, Nasuelli N, Cisari C, Massara M, Vercelli R, Oggioni GD, Carriero A, Cantello R, Monaco F, Fagioli F (2010) Mesenchymal stem cell transplantation in amyotrophic lateral sclerosis: a phase I clinical trial. Exp Neurol 223:229–237PubMedCrossRefGoogle Scholar
  19. Miller RH, Bai L, Lennon DP, Caplan AI (2010) The potential of mesenchymal stem cells for neural repair. Discov Med 9:236–242PubMedGoogle Scholar
  20. Park KW, Eglitis MA, Mouradian MM (2001) Protection of nigral neurons by GDNF-engineered marrow cell transplantation. Neurosci Res 40:315–323PubMedCrossRefGoogle Scholar
  21. Rossignol J, Boyer C, Lévèque X, Fink KD, Thinard R, Blanchard F, Dunbar GL, Lescaudron L (2011) Mesenchymal stem cell transplantation and DMEM administration in a 3NP rat model of Huntington’s disease: morphological and behavioral outcomes. Behav Brain Res 217:369–378PubMedCrossRefGoogle Scholar
  22. Sadan O, Shemesh N, Cohen Y, Melamed E, Offen D (2009) Adult neurotrophic factor-secreting stem cells: a potential novel therapy for neurodegenerative diseases. Isr Med Assoc J 11:201–204PubMedGoogle Scholar
  23. Schwarz EJ, Alexander GM, Prockop DJ, Azizi SA (1999) Multipotential marrow stromal cells transduced to produce L-DOPA: engraftment in rat model of Parkinson disease. Hum Gene Ther 10:2539–2549PubMedCrossRefGoogle Scholar
  24. Scuteri A, Miloso M, Foudah D, Orciani M, Cavaletti G, Tredici G (2011) Mesenchymal stem cells neuronal differentiation ability: a real perspective for nervous system repair? Curr Stem Cell Res Ther 6:82–92PubMedCrossRefGoogle Scholar
  25. Shi D, Chen G, Lv L, Li L, Wei D, Gu P, Gao J, Miao Y, Hu W (2011) The effect of lentivirus-mediated TH and GDNF genetic engineering mesenchymal stem cells on Parkinson’s disease rat model. Neurol Sci 32:41–51PubMedCrossRefGoogle Scholar
  26. Slavin S, Kurkalli BG, Karussis D (2008) The potential use of adult stem cells for the treatment of multiple sclerosis and other neurodegenerative disorders. Clin Neurol Neurosurg 110:943–946PubMedCrossRefGoogle Scholar
  27. Snyder BR, Chiu AM, Prockop DJ, Chan AW (2010) Human multipotent stromal cells (MSCs) increase neurogenesis and decrease atrophy of the striatum in a transgenic mouse model for Huntington’s disease. PLoS One 5:e9347PubMedCrossRefGoogle Scholar
  28. Vercelli A, Mereuta OM, Garbossa D, Muraca G, Mareschi K, Rustichelli D, Ferrero I, Mazzini L, Madon E, Fagioli F (2008) Human mesenchymal stem cell transplantation extends survival, improves motor performance and decreases neuroinflammation in mouse model of amyotrophic lateral sclerosis. Neurobiol Dis 31:395–405PubMedCrossRefGoogle Scholar
  29. Zappia E, Casazza S, Pedemonte E, Benvenuto F, Bonanni I, Gerdoni E, Giunti D, Ceravolo A, Cazzanti F, Frassoni F, Mancardi G, Uccelli A (2005) Mesenchymal stem cells ameliorate experimental autoimmune encephalomyelitis inducing T-cell anergy. Blood 106:1755–1761PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  1. 1.Department of Neuroscience and Biomedical Technologies, Faculty of MedicineUniversity of Milan-BicoccaMonzaItaly

Personalised recommendations